Short Interest in iBio, Inc. (NYSEAMERICAN:IBIO) Declines By 11.2%

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 230,900 shares, a decline of 11.2% from the October 31st total of 260,100 shares. Approximately 2.5% of the company’s stock are short sold. Based on an average daily trading volume, of 128,000 shares, the days-to-cover ratio is currently 1.8 days.

iBio Price Performance

NYSEAMERICAN:IBIO traded down $0.20 on Tuesday, hitting $2.60. 94,461 shares of the company’s stock were exchanged, compared to its average volume of 1,128,257. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. iBio has a 52 week low of $1.02 and a 52 week high of $4.98.

About iBio

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.